Dunad Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Dunad Therapeutics's estimated annual revenue is currently $2.7M per year.
- Dunad Therapeutics's estimated revenue per employee is $77,500
Employee Data
- Dunad Therapeutics has 35 Employees.
- Dunad Therapeutics grew their employee count by 46% last year.
Dunad Therapeutics's People
Name | Title | Email/Phone |
---|---|---|
1 | CEO | Reveal Email/Phone |
2 | SVP, Medicinal Chemistry | Reveal Email/Phone |
3 | SVP Drug Discovery | Reveal Email/Phone |
4 | Head Finance and Operations | Reveal Email/Phone |
5 | Head Bioinformatics | Reveal Email/Phone |
6 | Director Medicinal Chemistry | Reveal Email/Phone |
7 | Associate Director | Reveal Email/Phone |
8 | Senior Director Alliance and Project Management | Reveal Email/Phone |
9 | Director Computational Sciences | Reveal Email/Phone |
10 | Chief Scientific Officer | Reveal Email/Phone |
Dunad Therapeutics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $0.8M | 10 | 0% | N/A | N/A |
#2 | $2.7M | 35 | 46% | N/A | N/A |
#3 | $0.9M | 12 | 20% | N/A | N/A |
#4 | $0.8M | 10 | 11% | N/A | N/A |
#5 | $3.6M | 46 | 156% | $15M | N/A |
#6 | $2.4M | 31 | 82% | $10M | N/A |
#7 | $2.9M | 37 | 106% | $16M | N/A |
#8 | $2.6M | 33 | 22% | N/A | N/A |
What Is Dunad Therapeutics?
Dunad Therapeutics is a biopharmaceutical company focusing on the development of next-generation targeted oral protein degradation therapies. Dunad’s platform enables selective degradation via direct target modification using tunable mono-valent small molecules, allowing for the development of more drug-like, orally bioavailable and CNS-accessible protein degraders.
keywords:N/AN/A
Total Funding
35
Number of Employees
$2.7M
Revenue (est)
46%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $2.7M | 35 | -58% | $65M |
#2 | $4.1M | 35 | -33% | N/A |
#3 | $3.5M | 35 | 21% | N/A |
#4 | $5.9M | 35 | 6% | N/A |
#5 | $8M | 35 | 0% | N/A |